Product
ANK-101
1 clinical trial
8 indications
Indication
Advanced Solid TumorIndication
Skin TumorIndication
TumorIndication
Malignant Solid TumorIndication
Solid TumorIndication
Metastatic Solid TumorIndication
Metastasis to Soft TissueIndication
Lung CancerClinical trial
A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-01